MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer

Gelijkaardige items

• Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
  door: Zhang, Zhe, et al.
  Gepubliceerd in: (2019)
• EGFR/Met association regulates EGFR TKI resistance in breast cancer
  door: Mueller, Kelly L, et al.
  Gepubliceerd in: (2010)
• MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
  door: Presutti, Dario, et al.
  Gepubliceerd in: (2015)
• Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?
  door: Kanemura, Hiroaki, et al.
  Gepubliceerd in: (2020)
• Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR-T790M mutant lung cancer
  door: WANG, CHENGDE, et al.
  Gepubliceerd in: (2015)